These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31503332)

  • 1. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
    Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
    Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
    Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
    J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
    Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
    Shamai S; Merimsky O
    Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
    Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
    Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
    Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
    Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
    In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
    Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
    Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
    Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
    Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
    Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
    Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
    Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
    de Sande González LM; Martin-Broto J; Kasper B; Blay JY; Le Cesne A
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):957-963. PubMed ID: 32930637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.